Fibrogen INC 8-K filings

FibroGen, Inc. reports the resignation of three board members effective September 30, 2024, leading to new committee assignments.

FibroGen, Inc. has announced the departure of its Chief Financial Officer and Chief Medical Officer as part of an ongoing cost reduction plan.

FibroGen is implementing a restructuring plan, including a 75% reduction in its U.S. workforce, following negative clinical trial results for pamrevlumab.

FibroGen reports a 14% revenue increase driven by roxadustat sales in China, while implementing a significant cost reduction plan in the U.S. due to disappointing pancreatic cancer trial results.

FibroGen presented an update on the clinical development program for FG-3246, a novel antibody-drug conjugate targeting CD46, for metastatic castration-resistant prostate cancer (mCRPC).

FibroGen's stockholders approved the 2024 Equity Incentive Plan and elected three Class I directors at the company's annual meeting on June 5, 2024.

FibroGen's first quarter revenue increased by 55% year-over-year, driven by strong roxadustat sales in China and a one-time revenue recognition from the AstraZeneca agreement termination.

FibroGen announced its 2023 financial results, highlighted by increased revenue in China and a cost reduction plan, while also anticipating key clinical trial data in 2024.